Protective role of BDNF in Alzheimer's disease pathophysiology and its correlation with new biomarkers: Can the role of BDNF be re-discussed?

Basit Öğe Kaydı
dc.authoridCoskun, Erkam/0000-0001-5471-8606
dc.authoridAlayunt, Naci Omer/0000-0003-2215-0934
dc.contributor.authorTahiroglu, Veysel
dc.contributor.authorUgur, Elif
dc.contributor.authorCoskun, Erkam
dc.contributor.authorAlayunt, Naci Omer
dc.contributor.authorZorgor, Gulsah
dc.date.accessioned2024-12-24T19:30:21Z
dc.date.available2024-12-24T19:30:21Z
dc.date.issued2024
dc.departmentSiirt Üniversitesi
dc.description.abstractBackground. The pathophysiology of Alzheimer's disease (AD) is not fully understood and that new biomarkers for the condition should be presented. Objectives. Our study aimed to determine the blood levels of some biochemical molecules and peptide proteins in AD, which is accepted as the most common cause of dementia in the world, and to elucidate the relationship between them.Materials and methods. The study consisted of 2 groups: 40 newly diagnosed AD patients and 40 healthy individuals. Plasma levels between the 2 groups and the correlation between them were statistically analyzed.Results. The median brain-derived neurotrophic factor (BDNF) level in the AD group was found to be higher and statistically significant compared to the control group (p = 0.033).Conclusions. According to our literature review, this is the first article in which these molecules have been studied together in AD patients. In this study, we revealed the importance of these parameters and especially the instrumental role of BDNF in the form and function of the brain in AD patients. Interestingly, in the patient group, all parameters in our study showed a positive and significant positive relationship with one another (p < 0.001).
dc.description.sponsorshipSirnak University Scientific Research Projects Coordination Unit (BAP) [2022.FNAP. 18.03.01]
dc.description.sponsorshiphis work was financially supported by Sirnak University Scientific Research Projects Coordination Unit (BAP); Project No. 2022.FNAP. 18.03.01.
dc.identifier.doi10.17219/acem/172012
dc.identifier.endpage779
dc.identifier.issn1899-5276
dc.identifier.issn2451-2680
dc.identifier.issue8
dc.identifier.pmid38062654
dc.identifier.scopus2-s2.0-85202906645
dc.identifier.scopusqualityQ1
dc.identifier.startpage773
dc.identifier.urihttps://doi.org/10.17219/acem/172012
dc.identifier.urihttps://hdl.handle.net/20.500.12604/7503
dc.identifier.volume33
dc.identifier.wosWOS:001122060100001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWroclaw Medical Univ
dc.relation.ispartofAdvances in Clinical and Experimental Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241222
dc.subjectBDNF
dc.subjectAlzheimer's disease
dc.subjectcorrelation
dc.subjectbiomarkers
dc.titleProtective role of BDNF in Alzheimer's disease pathophysiology and its correlation with new biomarkers: Can the role of BDNF be re-discussed?
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu